<DOC>
	<DOCNO>NCT02413502</DOCNO>
	<brief_summary>The objective protocol obtain biological sample leukapheresis cryopreservation cell future study , vitro assay , immune response one dose BCG BCG-naïve healthy adult .</brief_summary>
	<brief_title>Leukapheresis Sampling Immune Responses After BCG Vaccination BCG-naïve Healthy Adults US</brief_title>
	<detailed_description>This open-label protocol 12 healthy adult BCG-naïve . All participant receive single dose BCG , percutaneous administration , Study Day 0 . There two follow-up visit Study Days 54 56 , telephone contact every 2 week visit . Leukapheresis conduct Study Days 0 56 . The Study Day 56 leukapheresis select base result functional biological assay suggest analysis sample time point may provide insight protective immune response elicit BCG . The study conduct single site US ( University Rochester Medical Center [ URMC ] ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Has complete write informed consent process . 2 . Is age ≥18 year ≤55 year Study Day 0 . 3 . Agrees stay contact study site duration study , provide update contact information necessary , current plan move study area duration study . 4 . Agrees avoid elective surgery study . 5 . Willingness receive HIV test result . 6 . For female participant : agree avoid pregnancy 21 day prior Study Day 0 full duration study . 7 . Has general good health , confirm medical history physical examination . 8 . Has receive vaccination immunotherapy BCG product time prior Study Day 0 . 1 . Acute illness Study Day 0 . 2 . HIV1/2 positive 3 . Oral temperature ≥37.5°C Study Day 0 . 4 . Abnormal laboratory value per local laboratory parameter recent blood collection prior Study Day 0 specific parameter list protocol . 5 . Evidence significant active infection . 6 . Evidence central nervous system tuberculosis pleural tuberculosis . 7 . Screening TST reaction &gt; 5 mm . 8 . History treatment active latent tuberculosis infection . 9 . History evidence active tuberculosis . 10 . Shared residence within last year individual antituberculosis treatment culture smear positive tuberculosis . 11 . History occupational exposure individual active tuberculosis health care set . 12 . History autoimmune disease immunosuppression . 13 . Used immunosuppressive medication within 42 day Study Day 0 ( inhaled topical corticosteroid permit ) . 14 . Received immunoglobulin blood product within 42 day Study Day 0 . 15 . Received investigational drug investigational vaccine within 182 day Study Day 0 , plan participation interventional study study period . 16 . Received investigational TB vaccine time . 17 . Planned administration/administration license vaccine period start 28 day end 56 day BCG vaccination study . 18 . Current chronic drug therapy include hormone replacement thyroxin , insulin , etc ( estrogen progesterone replacement contraceptive acceptable ) . 19 . History laboratory evidence past , present , future possible immunodeficiency state include limited laboratory indication HIV1 infection . 20 . No contraindication BCG administration describe BCG package insert ( Appendix B ) . 21 . Previous medical history may compromise safety participant study , include limited : severe impairment pulmonary function tuberculosis infection pulmonary disease ; chronic illness sign cardiac renal failure ; suspect progressive neurological disease ; uncontrolled epilepsy . 22 . Evidence new acute illness may compromise safety participant study . 23 . History evidence chronic hepatitis . 24 . History alcohol drug abuse within past 2 year . 25 . History keloid formation . 26 . Positive urine test illicit drug ( opiate , cocaine , amphetamine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>